Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Phase 2 Not yet recruiting 28 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the efficacy and safety of Iruplinalkib Tablets as postoperative adjuvant therapy in patients with stage IA, ALK-positive NSCLC with high-risk factors.

Timeline

Start: 2026-01-06
Primary completion: 2030-12-31
Completion: 2031-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Iruplinalkib	Unknown	180 mg	Oral

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Summary

Timeline

Drugs

Indications